| Jane Schnurr Parthum, RN, APNP | |
|
10500 W Loomis Rd Ste 130, Franklin, WI 53132-8030 | |
| (414) 488-1111 | |
| (414) 488-0700 |
| Full Name | Jane Schnurr Parthum |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Adult Health |
| Location | 10500 W Loomis Rd Ste 130, Franklin, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821300732 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2200X | Clinical Nurse Specialist - Adult Health | 66082-30 (Wisconsin) | Primary |
| Entity Name | Neurosurgery And Endovascular Assoc Of Milw Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063495000 PECOS PAC ID: 5698751790 Enrollment ID: O20040629000307 |
News Archive
Results of a Phase 2 study sponsored by Somnus Therapeutics, Inc., add further evidence supporting the efficacy and safety of a novel bedtime therapeutic that addresses a major underserved need of insomnia patients: maintaining sleep.
NanoBio Corporation today announced compelling preclinical data for NB-401, a nebulized nanoemulsion-based agent that kills highly drug-resistant strains of bacteria commonly found in cystic fibrosis patients. Currently there are limited treatment options available that effectively address these resistant bacteria. The study results are being presented today at the 2009 Annual North American Cystic Fibrosis Conference (NACFC) in Minneapolis, Minn.
Continua Health Alliance championed the use of personal connected healthcare technologies to increase veteran access to quality healthcare during last week's hearing of the House Committee on Veterans Affairs Subcommittee on Health. President and Chair of the Continua Board of Directors, Rick Cnossen, testified on behalf of the Alliance to address the issues facing veterans living in rural areas who typically receive lower quality healthcare than the general population due to lack of access.
Skin cancer patient Debra Gardocki receives an injection from oncologist Dr. Sanjiv Agarwala as part of a study exploring a new approach to treat advanced melanoma - an often fatal form of cancer for which there are limited effective treatment options.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jane Schnurr Parthum, RN, APNP 10500 W Loomis Rd Ste 130, Franklin, WI 53132-8030 Ph: (414) 488-1111 | Jane Schnurr Parthum, RN, APNP 10500 W Loomis Rd Ste 130, Franklin, WI 53132-8030 Ph: (414) 488-1111 |
News Archive
Results of a Phase 2 study sponsored by Somnus Therapeutics, Inc., add further evidence supporting the efficacy and safety of a novel bedtime therapeutic that addresses a major underserved need of insomnia patients: maintaining sleep.
NanoBio Corporation today announced compelling preclinical data for NB-401, a nebulized nanoemulsion-based agent that kills highly drug-resistant strains of bacteria commonly found in cystic fibrosis patients. Currently there are limited treatment options available that effectively address these resistant bacteria. The study results are being presented today at the 2009 Annual North American Cystic Fibrosis Conference (NACFC) in Minneapolis, Minn.
Continua Health Alliance championed the use of personal connected healthcare technologies to increase veteran access to quality healthcare during last week's hearing of the House Committee on Veterans Affairs Subcommittee on Health. President and Chair of the Continua Board of Directors, Rick Cnossen, testified on behalf of the Alliance to address the issues facing veterans living in rural areas who typically receive lower quality healthcare than the general population due to lack of access.
Skin cancer patient Debra Gardocki receives an injection from oncologist Dr. Sanjiv Agarwala as part of a study exploring a new approach to treat advanced melanoma - an often fatal form of cancer for which there are limited effective treatment options.
› Verified 8 days ago